Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cholesterol catabolism pathway in Mycobacterium tuberculosis (Mtb) is a crucial metabolic process that enables the bacterium to utilize host-derived cholesterol as a carbon and energy source during infection. This pathway is essential for Mtb’s survival, persistence, and virulence within the host, particularly inside macrophages. The pathway involves cholesterol uptake, side chain degradation, ring cleavage, and integration of catabolic products into central metabolic pathways. Key proteins involved include mce4 (cholesterol transporter), CYP125/CYP142/CYP124 (cytochrome P450s for side-chain oxidation), and KstR/KstR2 (transcriptional regulators). Targeting this pathway represents a potential therapeutic strategy for tuberculosis.
Inhibition of cholesterol uptake, side chain oxidation, or ring cleavage, leading to disruption of bacterial energy production and survival.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholesterol Catabolism Pathway in Mycobacterium tuberculosis (Cholesterol Catabolism Pathway (Mtb)).